Ying-Hwa Chen1,2, Hsiao-Huang Chang3, Po-Lin Chen3, Zen-Chung Weng4, I-Ming Chen3, Hsin-Bang Leu1,2,5, Chun-Yang Huang3, Su-Man Lin6, Mei-Han Wu7. 1. Division of Cardiology, Department of Internal Medicine, Taipei Veterans General Hospital. 2. School of Medicine, National Yang-Ming University. 3. Division of Cardiovascular Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei. 4. Division of Cardiovascular Surgery, Wei Gong Memorial Hospital, Miaoli. 5. Division of Healthcare and Management, Healthcare Center. 6. Department of Anesthesiology. 7. Department of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan.
Abstract
BACKGROUND: This is the first study of a Taiwanese population reporting transcatheter aortic valve implantation (TAVI) outcomes of the first 100 cases from a single center offering two different transcatheter heart valve technologies via six types of approaches. We herein report the 30-day and one-year outcomes in our first 100 TAVI patients at Taipei Veterans General Hospital. METHODS: From May 2010 to April 2016, 100 consecutive patients with severe aortic stenosis (AS) who were considered unsuitable or at high risk for surgical aortic valve replacement underwent TAVI. Patient outcomes were classified according to the Valve Academic Research Consortium-2 (VARC-2) definitions. The device performance was assessed using transthoracic echocardiography by independent investigators. RESULTS: The mean patient age was 81.1 years, where 54% were female, and the mean Logistic EuroSCORE was 21.5%. The Medtronic CoreValve was used in 84 patients and the Edwards Sapien or Sapien XT valve (ESV) in 16. The transfemoral approach was the most frequently used route (83%), followed by transapical (9%) access. Overall, there was no procedural death. The VARC-2 outcomes were as follows: device success, 95%; stroke, 1%; major vascular complication, 3%; a need for pacemaker implantation, 5.1%. At discharge, the incidence of postoperative mild, moderate or severe paravalvular leak was 30%, 3% and 0%, respectively. At one year, the all-cause mortality rate was 14.0%, and no valve-related dysfunction was observed. Through multivariable analysis, non-transfemoral access [hazard ratios (HR) 4.81; 95% confidence interval (CI) 1.66-14.09; p = 0.004] and advanced chronic kidney disease (stages 4-5), (HR 3.13; 95% CI 1.07-9.09; p = 0.036) were independently associated with an increased risk of one-year mortality. CONCLUSIONS: We demonstrated that TAVI shows good early and mid-term outcomes in terms of survival, technical success, valve-related adverse events and haemodynamic performance in high-risk patients with severe AS.
BACKGROUND: This is the first study of a Taiwanese population reporting transcatheter aortic valve implantation (TAVI) outcomes of the first 100 cases from a single center offering two different transcatheter heart valve technologies via six types of approaches. We herein report the 30-day and one-year outcomes in our first 100 TAVI patients at Taipei Veterans General Hospital. METHODS: From May 2010 to April 2016, 100 consecutive patients with severe aortic stenosis (AS) who were considered unsuitable or at high risk for surgical aortic valve replacement underwent TAVI. Patient outcomes were classified according to the Valve Academic Research Consortium-2 (VARC-2) definitions. The device performance was assessed using transthoracic echocardiography by independent investigators. RESULTS: The mean patient age was 81.1 years, where 54% were female, and the mean Logistic EuroSCORE was 21.5%. The Medtronic CoreValve was used in 84 patients and the Edwards Sapien or Sapien XT valve (ESV) in 16. The transfemoral approach was the most frequently used route (83%), followed by transapical (9%) access. Overall, there was no procedural death. The VARC-2 outcomes were as follows: device success, 95%; stroke, 1%; major vascular complication, 3%; a need for pacemaker implantation, 5.1%. At discharge, the incidence of postoperative mild, moderate or severe paravalvular leak was 30%, 3% and 0%, respectively. At one year, the all-cause mortality rate was 14.0%, and no valve-related dysfunction was observed. Through multivariable analysis, non-transfemoral access [hazard ratios (HR) 4.81; 95% confidence interval (CI) 1.66-14.09; p = 0.004] and advanced chronic kidney disease (stages 4-5), (HR 3.13; 95% CI 1.07-9.09; p = 0.036) were independently associated with an increased risk of one-year mortality. CONCLUSIONS: We demonstrated that TAVI shows good early and mid-term outcomes in terms of survival, technical success, valve-related adverse events and haemodynamic performance in high-risk patients with severe AS.
Authors: Polykarpos C Patsalis; Fadi Al-Rashid; Till Neumann; Björn Plicht; Heike A Hildebrandt; Daniel Wendt; Matthias Thielmann; Heinz G Jakob; Gerd Heusch; Raimund Erbel; Philipp Kahlert Journal: JACC Cardiovasc Interv Date: 2013-09 Impact factor: 11.195
Authors: David S Bach; Derrick Siao; Steven E Girard; Claire Duvernoy; Benjamin D McCallister; Sarah K Gualano Journal: Circ Cardiovasc Qual Outcomes Date: 2009-10-27
Authors: Craig R Smith; Martin B Leon; Michael J Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; Mathew Williams; Todd Dewey; Samir Kapadia; Vasilis Babaliaros; Vinod H Thourani; Paul Corso; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Jodi J Akin; William N Anderson; Duolao Wang; Stuart J Pocock Journal: N Engl J Med Date: 2011-06-05 Impact factor: 91.245
Authors: Corrado Tamburino; Davide Capodanno; Angelo Ramondo; Anna Sonia Petronio; Federica Ettori; Gennaro Santoro; Silvio Klugmann; Francesco Bedogni; Francesco Maisano; Antonio Marzocchi; Arnaldo Poli; David Antoniucci; Massimo Napodano; Marco De Carlo; Claudia Fiorina; Gian Paolo Ussia Journal: Circulation Date: 2011-01-10 Impact factor: 29.690
Authors: Samuel V Lichtenstein; Anson Cheung; Jian Ye; Christopher R Thompson; Ronald G Carere; Sanjeevan Pasupati; John G Webb Journal: Circulation Date: 2006-07-31 Impact factor: 29.690
Authors: Vinod H Thourani; Jessica Forcillo; Nirat Beohar; Darshan Doshi; Rupa Parvataneni; Girma M Ayele; Ajay J Kirtane; Vasilis Babaliaros; Susheel Kodali; Chandan Devireddy; Wilson Szeto; Howard C Herrmann; Raj Makkar; Gorav Ailawadi; Scott Lim; Hersh S Maniar; Alan Zajarias; Rakesh Suri; E Murat Tuzcu; Samir Kapadia; Lars Svensson; Jose Condado; Hanna A Jensen; Michael J Mack; Martin B Leon Journal: Ann Thorac Surg Date: 2016-09-01 Impact factor: 4.330
Authors: Stefan Toggweiler; Ronen Gurvitch; Jonathon Leipsic; David A Wood; Alexander B Willson; Ronald K Binder; Anson Cheung; Jian Ye; John G Webb Journal: J Am Coll Cardiol Date: 2012-01-10 Impact factor: 24.094
Authors: A Pieter Kappetein; Stuart J Head; Philippe Généreux; Nicolo Piazza; Nicolas M van Mieghem; Eugene H Blackstone; Thomas G Brott; David J Cohen; Donald E Cutlip; Gerrit-Anne van Es; Rebecca T Hahn; Ajay J Kirtane; Mitchell W Krucoff; Susheel Kodali; Michael J Mack; Roxana Mehran; Josep Rodés-Cabau; Pascal Vranckx; John G Webb; Stephan Windecker; Patrick W Serruys; Martin B Leon Journal: J Am Coll Cardiol Date: 2012-10-09 Impact factor: 24.094
Authors: Francesca Giordana; Fabrizio D'Ascenzo; Freek Nijhoff; Claudio Moretti; Maurizio D'Amico; Giuseppe Biondi Zoccai; Jan Malte Sinning; George Nickenig; Nicolas M Van Mieghem; Adelaide Chieffo; Nicolas Dumonteil; Didier Tchetche; Israel M Barbash; Ron Waksman; Augusto D'Onofrio; Thierry Lefevre; Thomas Pilgrim; Nicolas Amabile; Pablo Codner; Ran Kornowski; Ze Yie Yong; Jan Baan; Antonio Colombo; Azeem Latib; Stefano Salizzoni; Pierluigi Omedè; Federico Conrotto; Michele La Torre; Sebastiano Marra; Mauro Rinaldi; Fiorenzo Gaita Journal: Am J Cardiol Date: 2014-08-13 Impact factor: 2.778